Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR

Bank of Montreal Can grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 160.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,209 shares of the biopharmaceutical company's stock after acquiring an additional 17,381 shares during the quarter. Bank of Montreal Can's holdings in Xencor were worth $222,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of XNCR. CWM LLC grew its holdings in Xencor by 195.5% in the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Xencor by 8.3% in the 1st quarter. Wellington Management Group LLP now owns 29,776 shares of the biopharmaceutical company's stock valued at $317,000 after purchasing an additional 2,285 shares during the last quarter. State of Wyoming purchased a new stake in shares of Xencor during the 1st quarter valued at $34,000. State of Alaska Department of Revenue grew its stake in shares of Xencor by 9.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 42,351 shares of the biopharmaceutical company's stock valued at $332,000 after buying an additional 3,574 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock worth $471,000 after buying an additional 3,692 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts recently weighed in on XNCR shares. Wedbush reiterated an "outperform" rating and issued a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Wells Fargo & Company decreased their target price on Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Royal Bank Of Canada increased their target price on shares of Xencor from $18.00 to $19.00 and gave the stock an "outperform" rating in a research report on Thursday, November 6th. Cantor Fitzgerald raised their price target on shares of Xencor from $40.00 to $42.00 and gave the company an "overweight" rating in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Xencor from $20.00 to $18.00 and set an "overweight" rating for the company in a research note on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $24.63.

Check Out Our Latest Research Report on Xencor

Xencor Stock Performance

Xencor stock opened at $15.57 on Friday. The stock's 50 day moving average price is $12.90 and its 200 day moving average price is $9.95. The firm has a market capitalization of $1.11 billion, a PE ratio of -6.49 and a beta of 0.99. Xencor, Inc. has a one year low of $6.92 and a one year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.64. The company had revenue of $21.00 million during the quarter, compared to the consensus estimate of $29.73 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. Xencor's revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.71) earnings per share. On average, analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Read More

• Five stocks we like better than Xencor
• What Are Dividend Champions? How to Invest in the Champions
• Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?
• Golden Cross Stocks: Pattern, Examples and Charts
• Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?
• What is a Secondary Public Offering? What Investors Need to Know
• Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Xencor Right Now?

Before you consider Xencor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.

While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here